ClinicalTrials.gg
RecruitingNCT06943469SPHINXUpdated Jul 30, 2026

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

An interventional study of Test formula and Control formula in Atopic Dermatitis (AD), sponsored by Société des Produits Nestlé (SPN). Recruiting at 25 sites in 5 countries. Open to participants aged 1 Day to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
1 Day to 14 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Dermatitis, Atopic with a site in Spain — 10 open to participants now, 30 under way, 12 of them phase 3. Dermatitis, Atopic · Spain.

Planned enrollment
43rd of 104
400 · median 306
Started
2025
with 9 others
No phase
12 of 113
1 open now
Primary completion
2027-10
later than 16 of 29 live
Registered
103rd of 113
by date

Among the 113 studies in Dermatitis, Atopic with a site in Spain, this one is the 43rd largest by planned enrollment of the 104 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 with no phase, reaches primary completion later than 16 of the 29 other live ones, and was the 103rd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

10 of the 113 studies in Dermatitis, Atopic with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 1 Day to 14 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Dermatitis, Atopic with a site in Spain, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
1 Day to 14 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written has been obtained from at least one parent or legally acceptable representative (LAR), if applicable
  2. Infant gestational age ≥ 37 completed weeks
  3. Infant birth weight of ≥ 2.5 kg and ≤ 4.5 kg
  4. Infant postnatal age ≤ 14 days (date of birth = day 0) at enrollment
  5. Infant from singleton birth or infant from multiple births may if all birth siblings are enrolled.
  6. At least one biological parent or sibling has (or had) a medically diagnosed history of allergy, based on response to a simple screening questionnaire
  7. a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.

    or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.

  8. Parents/LAR must be able to provide evidence of parental authority and identity.
  9. Infant's parent(s)/LAR must understand the informed consent form and other study documents and are willing and able to fulfill the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Infectious, metabolic, congenital, genetic, gastrointestinal illness or any other condition (e.g., gastrointestinal surgery) that could impact oral feeding, growth or study outcomes.
  2. Infants with special dietary needs other than standard infant formula (e.g., extensively hydrolyzed formula, amino acid formula, special formula for metabolic diseases) or requiring tube feeding.
  3. Infant has already been diagnosed with allergy by a physician, including AD and/or cow's milk allergy.
  4. Infant is currently participating or has previously participated in another clinical trial prior to enrollment.
  5. Infant's parents or LARs have not reached legal age of majority (18 years).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Test formula

    Partially hydrolyzed formula with synbiotics

    Other: Test formula

  • Active comparator
    Control formula

    Intact protein formula without synbiotics

    Other: Control formula

  • No intervention
    Reference arm

    Breastfed arm (not applicable for France)

Interventions

  • OtherTest formula

    Partially hydrolyzed formula with synbiotics

  • OtherControl formula

    Intact protein formula without synbiotics

06

What researchers measure

Primary outcomes

  1. TransEpidermal Water Loss (TEWL) at 3 months

    TransEpidermal water loss will be measured using a validated non-invasive technique.

    Time frame: At 3 months of age

Secondary outcomes

  1. Cumulative incidence of Atopic Dermatitis

    Cumulative incidence of AD is based on physician diagnosis using the United Kingdom Working Party (UKWP) diagnosis criteria.

    Time frame: From enrollment to 12 months of age

  2. TransEpidermal Water Loss

    Epidermal water loss will be measured using a validated non-invasive technique.

    Time frame: From enrollment to 12 months of age

  3. Skin surface (stratum corneum) hydration

    Skin hydration will be measured with a corneometer device.

    Time frame: From enrollment to 12 months of age

  4. Extent and severity of Atopic Dermatitis

    SCORAD (SCORing for Atopic Dermatitis), scores range from 0 to 103, with higher scores indicating higher atopic dermatitis severity

    Time frame: From 3 months to 12 months of age

  5. Cumulative use of topical steroids and calcineurin inhibitors

    Use of medication to treat AD and other symptoms will be collected via parent self-reported questionnaire.

    Time frame: From enrollment to 12 months of age

  6. Skin cytokines

    Concentration of skin cytokines such as IL4 and IL5 using immunoassays

    Time frame: From enrollment to 12 months of age

  7. Skin natural moisturizing factors

    Concentration of skin natural moisturizing factors such as Pyrrolidone carboxylic acid, using HPLC

    Time frame: From enrollment to 12 months of age

  8. Skin stratum corneum lipids

    Concentration of skin stratum corneum lipids such as ceramides, cholesterol and triacylglycerol using mass spectrometry

    Time frame: From enrollment to 12 months of age

  9. Skin microbiome

    Overall skin microbiome composition and diversity using next-generation sequencing

    Time frame: From enrollment to 12 months of age

  10. Skin metabolites

    Levels of skin metabolites using targeted or untargeted approaches.

    Time frame: From enrollment to 12 months of age

  11. Immune proteomics

    Levels of plasma proteins using mass cytometry or immunoassaysand immunoassays.

    Time frame: From enrollment to 6 months of age

  12. Immune blood cell immunophenotyping

    Levels of immune cell populations using mass cytometry or immunoassays

    Time frame: From enrollment to 6 months of age

  13. Specific IgE antibodies

    Specific IgE antibodies will be measured using Phadiatop infant®.

    Time frame: At 12 months of age

  14. Fecal microbiome

    Overall fecal microbiota composition, diversity, different bacteria taxa and microbiota community types assessed using next generation sequencing (NGS) technology

    Time frame: From enrollment to 12 months of age

  15. Fecal metabolites

    Levels of fecal metabolites using targeted or untargeted approaches.

    Time frame: From enrollment to 12 months of age

  16. Fecal biomarkers of inflammation and immunity

    Levels of fecal markers of immune health and inflammation such as total secretory IgA (sIgA), calprotectin, and α-1-antitrypsin assessed by ELISA.

    Time frame: From enrollment to 12 months of age

  17. Physician-diagnosed allergic manifestations

    Number of participants with Physician-diagnosed allergic manifestations.

    Time frame: From enrollment to 12 months of age

  18. Gastrointestinal tolerance

    Infant Gastrointestinal Symptom Questionnaire (IGSQ), scores range from 13 to 65, with higher scores indicating higher gastrointestinal discomfort.

    Time frame: At enrollment and 4 months of age

  19. Weight

    Weight (g and z-scores)

    Time frame: From enrollment to 12 months of age

  20. Height

    Length (cm and z-scores)

    Time frame: From enrollment to 12 months of age

  21. Head circumference

    Head circumference (cm and z-scores)

    Time frame: From enrollment to 12 months of age

  22. Safety assessment

    Incidence of adverse events

    Time frame: From enrollment to 13 months of age

07

Study locations

19 of 25 sites recruiting
  • AZ Sint-Jan Brugge-Oostende AV - Campus Sint-Jan
    Bruges, Belgium
    Recruiting
    • Luc Cornette, Dr · Contact
  • Universitair Ziekenhuis Brussel - Kinderziekenhuis
    Brussels, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinique Ste Elisabeth
    Namur, Belgium
    Recruiting
    • Sabine Jespers, Dr · Contact
  • CHU Amiens Picardie
    Amiens, France
    Recruiting
    • André Léké, Dr · Contact
  • CHU de Caen
    Caen, France
    Recruiting
    • Geraldine Favrais, Pr · Contact
  • CHU de Grenoble Alpes
    Grenoble, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hôpital de la Croix Rousse
    Lyon, France
    Recruiting
    • Jean-Charles Picaud, Pr · Contact
  • Hôpital Charles Nicolle
    Rouen, France
    Recruiting
    • Mireille Castanet, Dr · Contact
  • CHRU de Tours
    Tours, France
    Recruiting
    • Kristen Joseph-Delaffon, Dr · Contact
  • Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)
    Berlin, Germany
    Not yet recruiting
    • Kirsten Beyer, Pr · Contact
  • Evangelisches Krankenhaus Düsseldorf - Frauenklinik
    Düsseldorf, Germany
    Recruiting
    • Monika Gappa, Pr · Contact
  • Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Frankfurt
    Frankfurt, Germany
    Recruiting
    • Katharina Bluemchen, PD Dr · Contact
  • Evangelisches Waldkrankenhaus Spandau
    Spandau, Germany
    Recruiting
    • Frank Jochum, PD Dr · Contact
  • Marien Hospital Wesel GmbH
    Wesel, Germany
    Recruiting
    • Willem Geurts van Kessel, Dr · Contact
  • Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny
    Bialystok, Poland
    Not yet recruiting
  • BioMedical Centers
    Warsaw, Poland
    Not yet recruiting
  • Hospital Teresa Herrera
    A Coruña, Spain
    Recruiting
    • Ana Moreno Álvarez, Dr · Contact
  • HU Torrecárdenas
    Almería, Spain
    Recruiting
    • Rafael Galera Martínez, Dr · Contact
  • Hospital Quiron Salud Barcelona
    Barcelona, Spain
    Recruiting
    • Hector Boix, Dr · Contact
  • Hospital Universitario Severo Ochoa
    Madrid, Spain
    Recruiting
    • Inge Silveria Alonso Larruscain, Dr · Contact
  • Grupo Pediátrico Uncibay
    Málaga, Spain
    Recruiting
    • Manuel Ramón Baca Cots, Dr · Contact
  • Instituto Hispalense de Pediatria (IHP)
    Seville, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Universitari de Tarragona Joan XXIII
    Tarragona, Spain
    Recruiting
    • Esther Parada Ricart, Dr · Contact
  • Hospital Universitari Sant Joan de Reus
    Tarragona, Spain
    Recruiting
    • Joaquín Escribano Subias, Dr · Contact
  • HCU Lozano Blesa
    Zaragoza, Spain
    Recruiting
    • Gerardo Rodríguez Martínez, Dr · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 69 industry-sponsored interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 30 months is above that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 24, 2025
StartActual
Apr 10, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Nov 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06943469
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Apr 10, 2025
Primary completion
Oct 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Amelie Goyer, PhD
Contact
Amelie.Goyer1@rd.nestle.com
+41217858939

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion